Dr. Reddy's Laboratories Limited (DRREDDY) Net Income 2022–TTM

Name: Dr. Reddy's Laboratories Limited (DRREDDY) net income history 2022-TTM
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

DATA UPDATED 2026-11-02

Dr. Reddy's Laboratories Limited annual net income for fiscal TTM was ₹28.0 billion, a decrease of 34.7% from ₹42.9 billion in fiscal 2026. All figures are reported results from public filings — no estimates or projections.

DRREDDY Annual Net Income

Net Income (annual)	TTM → 2026-09-30	2026-03-31	2025-03-31	2024-03-31	2023-03-31	2022-03-31
Net Income	₹28.0B	₹42.9B	₹56.5B	₹55.7B	₹45.1B	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

DRREDDY Quarterly Net Income

Net Income (quarterly)	2026-09-30	2026-06-30	2026-03-31	2025-12-31	2025-09-30	2025-06-30	2025-03-31
Net Income	₹9.2B	₹4.4B	₹2.2B	₹12.1B	₹14.4B	—	—

INR; ₹M / ₹B as marked (reporting currency). Newest period first. Source: public company filings (via Yahoo Finance aggregation).

Net Income at Comparable Companies

4523 Net Income — Eisai Co., Ltd.
4151 Net Income — Kyowa Kirin Co., Ltd.
LAURUSLABS Net Income — Laurus Labs Limited
ZYDUSLIFE Net Income — Zydus Lifesciences Limited
CIPLA Net Income — Cipla Limited
AUROPHARMA Net Income — Aurobindo Pharma Limited

More DRREDDY metrics: Revenue · Gross Profit · Operating Income · EPS · Free Cash Flow

All DRREDDY financial statements → Interactive DRREDDY charts →

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.